Eloxx (ELOX) CEO Sumit Aggarwal Receives Option Award

What Happened Sumit Aggarwal, President, CEO and Director of Eloxx Pharmaceuticals (ELOX), was reported as acquiring a derivative award of 328,833 shares on June 10, 2026. The Form 4 shows the award at $0.00 (no cash paid). This is an equity option/award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: June 10, 2026. Transaction type: Award/Grant (derivative).
• Shares/units involved: 328,833 (reported as acquired). Reported price: $0.00.
• Footnote: The option was originally granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. As a result, the option became eligible to vest on a time-based schedule.
• Vesting schedule: The option will vest 1/36 on July 31, 2026, with the remaining shares vesting in equal monthly installments over the next 35 months, subject to the insider’s continued service.
• Shares owned after the transaction: Not specified in the provided excerpt.
• Filing timeliness: Reported and filed with a Form 4 dated June 10, 2026 (appears timely).

Context This filing reflects an award/option rather than a cash purchase or a sale. The performance condition being satisfied triggered the start of a multi-year, time-based vesting schedule; it does not indicate immediate sale or exercise. For retail investors, awards like this show management compensation alignment with company performance and retention, but do not by themselves signal a buy or sell action in the market.